肯尼亚西部高传播区社区大规模检测与治疗对疟疾感染率的影响:整群随机对照试验
该整群随机对照试验在肯尼亚西部高传播区评估每年3轮、持续2年的社区大规模检测与治疗(MTaT)对疟疾感染率的影响。结论提示该干预未降低疟疾寄生虫患病率。
要点
- 每年3轮、持续2年的社区MTaT未降低高传播区疟疾感染率。
- 第1年和第2年调整后效果量分别为0.93和0.92,置信区间均包含1。
- MTaT覆盖率第1年75.0%-77.5%,第2年81.9%-94.3%。
核心结论
- 在肯尼亚西部高传播区,每年3轮、持续2年的社区MTaT未降低疟疾寄生虫患病率。
研究设计与样本
- 社区健康志愿者入户对同意者进行快速诊断检测,阳性者用双氢青蒿素哌喹治疗。
- 两臂在基线和每年3轮MTaT后开展横断面社区感染率调查,主要结局为显微镜下寄生虫患病率的组间效果量。
主要发现
- 各调查时点两臂人口学和行为特征(包括LLIN使用)相似。
- MTaT覆盖率第1年为75.0%-77.5%,第2年为81.9%-94.3%。
临床怎么用
- 在高传播区,每年3轮社区MTaT alone不足以降低疟疾感染率,需结合其他干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Global gains toward malaria elimination have been heterogeneous and have recently stalled. Interventions targeting afebrile malaria infections may be needed to address residual transmission. We studied the efficacy of repeated rounds of community-based mass testing and treatment (MTaT) on malaria infection prevalence in western Kenya. METHODS: Twenty clusters were randomly assigned to 3 rounds of MTaT per year for 2 years or control (standard of care for testing and treatment at public health facilities along with government-sponsored mass long-lasting insecticidal net [LLIN] distributions). During rounds, community health volunteers visited all households in intervention clusters and tested all consenting individuals with a rapid diagnostic test. Those positive were treated with dihydroartemisinin-piperaquine. Cross-sectional community infection prevalence surveys were performed in both study arms at baseline and each year after 3 rounds of MTaT. The primary outcome was the effect size of MTaT on parasite prevalence by microscopy between arms by year, adjusted for age, reported LLIN use, enhanced vegetative index, and socioeconomic status. RESULTS: Demographic and behavioral characteristics, including LLIN usage, were similar between arms at each survey. MTaT coverage across the 3 annual rounds ranged between 75.0% and 77.5% in year 1, and between 81.9% and 94.3% in year 2. The adjusted effect size of MTaT on the prevalence of parasitemia between arms was 0.93 (95% confidence interval [CI], .79-1.08) and 0.92 (95% CI, .76-1.10) after year 1 and year 2, respectively. CONCLUSIONS: MTaT performed 3 times per year over 2 years did not reduce malaria parasite prevalence in this high-transmission area. CLINICAL TRIALS REGISTRATION: NCT02987270.
引用
- Samuels AM, Odero NA, Odongo W, et al. Impact of Community-Based Mass Testing and Treatment on Malaria Infection Prevalence in a High-Transmission Area of Western Kenya: A Cluster Randomized Controlled Trial. Clin Infect Dis. 2021. PMID: 32324850. doi:10.1093/cid/ciaa471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。